One shot to rule them all? new vaccine targets five meningococcal strains in infants

NCT ID NCT05082285

Completed ⭐️ VACCINE ⭐️ Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new combination vaccine designed to protect healthy infants against five types of meningococcal bacteria (A, B, C, W, and Y) that can cause serious infections like meningitis. Over 700 infants received different doses or combinations of the vaccine to check safety and immune response. The goal is to see if this combined shot can offer broad protection with fewer injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Meningococcal combined ABCWY vaccine

What this could lead to

If successful, this vaccine could protect infants against five types of meningococcal bacteria with fewer shots, reducing the risk of serious infections like meningitis.

What could go wrong

This is an early phase 2 trial, so the vaccine may not prove effective enough or could cause side effects. Results in infants may differ from older age groups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFECTIONS, MENINGOCOCCAL

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Santo Domingo Este, Dominican Republic
GSK Investigational Site

Espoo, 02230, Finland
GSK Investigational Site

Helsinki, 00100, Finland
GSK Investigational Site

Jarvenpaa, 04400, Finland
GSK Investigational Site

Kokkola, 67100, Finland
GSK Investigational Site

Oulu, 90220, Finland
GSK Investigational Site

Seinäjoki, 60100, Finland
GSK Investigational Site

Gilching, 82205, Germany
GSK Investigational Site

Schönau am Königssee, 83471, Germany
GSK Investigational Site

San Pedro Sula, 21101, Honduras
GSK Investigational Site

Bydgoszcz, 85-048, Poland
GSK Investigational Site

Krakow, 30-348, Poland
GSK Investigational Site

Krakow, 30-644, Poland
GSK Investigational Site

Luboń, 62-030, Poland
GSK Investigational Site

Siemianowice Śląskie, 41-103, Poland
GSK Investigational Site

Torun, 87-100, Poland
GSK Investigational Site

Trzebnica, 55-100, Poland
GSK Investigational Site

Warsaw, 02-647, Poland
GSK Investigational Site

Wroclaw, 50368, Poland
GSK Investigational Site

Parow Valley, 7505, South Africa
GSK Investigational Site

Soweto Gauteng, 2013, South Africa
GSK Investigational Site

Almería, 04120, Spain
GSK Investigational Site

Burgos, 09006, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28222, Spain
GSK Investigational Site

Marbella, 29600, Spain
GSK Investigational Site

Málaga, 29004, Spain
GSK Investigational Site

Santiago de Compostela, 15706, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Exeter, EX2 5DW, United Kingdom
GSK Investigational Site

Oxford, OX3 7LE, United Kingdom